QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 专题：北京大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Effect of Non-Thermal Plasma-Activated Water on Fruit Decay and Quality in Postharvest Chinese Bayberries 期刊论文 FOOD AND BIOPROCESS TECHNOLOGY, 2016 Ma, Ruonan; Yu, Shuang; Tian, Ying; Wang, Kaile; Sun, Chongde; Li, Xian; Zhang, Jue; Chen, Kunsong; Fang, Jing 收藏  |  浏览/下载：11/0  |  提交时间：2017/12/03 Chinese bayberry  Non-thermal plasma-activated water  Fruit decay  Microbial loads  Fruit quality  Reactive oxygen species  RADICAL SCAVENGING ACTIVITY  LOW-TEMPERATURE PLASMA  ANTIOXIDANT CAPACITY  MICROBIAL INACTIVATION  METHYL JASMONATE  BOTRYTIS-CINEREA  DECONTAMINATION  ANTHOCYANINS  SUSCEPTIBILITY  STERILIZATION   Differential phase-contrast interior tomography 其他 2012-01-01 Cong, Wenxiang; Yang, Jiangsheng; Wang, Ge 收藏  |  浏览/下载：3/0  |  提交时间：2015/11/16 RAY TALBOT INTERFEROMETRY  IMAGE-RECONSTRUCTION  HILBERT TRANSFORM   Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest 期刊论文 investigational new drugs, 2011 Fu, Jia-ning; Li, Jing; Tan, Qiang; Yin, Han-wei; Xiong, Kun; Wang, Tian-yu; Ren, Xiao-yuan; Zeng, Hui-hui 收藏  |  浏览/下载：3/0  |  提交时间：2015/11/10 Ethaselen  Cisplatin  Combination index  Cell cycle regulation  LoVo  DNA-DAMAGE  QUANTITATIVE-ANALYSIS  INDUCED CYTOTOXICITY  POSSIBLE INVOLVEMENT  CYCLE  APOPTOSIS  P53  MECHANISM  GROWTH  UCN-01   Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide-Sensitive and -Resistant HIV Type 1 Strains 期刊论文 病毒学杂志, 2009 Pan, Chungen; Cai, Lifeng; Lu, Hong; Qi, Zhi; Jiang, Shibo 收藏  |  浏览/下载：3/0  |  提交时间：2015/11/13 CELL-CELL FUSION  ENTRY INHIBITORS  MEMBRANE-FUSION  IN-VITRO  MULTIFUNCTIONAL DOMAINS  ANTIRETROVIRAL ACTIVITY  PHENOTYPIC RESISTANCE  ENVELOPE GLYCOPROTEIN  CLINICAL RESISTANCE  ATOMIC-STRUCTURE